Stay in Touch
To keep in touch, please sign up to the Milltrust Ventures Newsletter for our latest news and insights.
Viome, an investee company through Milltrust’s partnership with Cerracap Ventures, is focused on disrupting healthcare by “making illness optional”. The Viome test is a breakthrough microbiome bacteria, epigenetics, epigenome and epigenomics technology.
Milltrust has a block of USD 5 million at a 20 percent discount to the last raise. Contact us for more information.
Tags: Healthcare Science Technology viome